GNTA starts pivotal Genasense trial

Genta (GNTA) began an open-label U.S. Phase III trial of its Genasense in up to 270 patients with non-small cell lung cancer (NSCLC). The trial will compare Genasense plus Taxotere docetaxel from Aven...